Just the Facts:

Co-pay as low as

$0

for commercially
insured patients*

Instant savings at
>70,000 pharmacies nationwide† with no cards, coupons, or calls

Just the Facts:

FDA-approved drugs generally have

Broader coverage with fewer restrictions

than compounded medicines18

Azurity Is Helping Make Products Accessible for Your Patients

Available at most pharmacies within 24 hours

Orange hexagon with text Paperless Co-pay Support

Discounts available to patients with commercial insurance

Instant savings: no cards, coupons, or apps required

Available at >70,000 pharmacies nationwide†

Cyan hexagon with text Bridge Drug Program

Covers the gap when insurance approval takes more than 48 hours

Up to 30 days of medication at no cost

Blue hexagon with text Patient Assistance Program

Need-based financial support

A safety net for uninsured patients

*Eligibility restrictions and terms and conditions may apply.

†Approximate participating pharmacies for eVoucherRx™ and Voucher on Demand™.

eVoucherRx™ is a trademark of RelayHealth. Voucher on Demand™ is a trademark of eRx Network, LLC.

Comprehensive Support for You and Your Patients From Office to Pharmacy

Azurity Solutions works with your staff to simplify access and approvals

Green hexagon with text CoverMyMeds

A trusted third-party online resource to manage prior authorizations (PAs)

100% free to use, secure, and paperless

Works with electronic PA systems at most major plans

Greenish blue hexagon with text Prior Authorization Hotline

Dedicated expert hotline: 844-472-2032

Live support for prescriber offices and pharmacies

Facilitates PAs, insurance verification, and more

droplet

Learn more about how we can help make our products affordable and accessible for your patients.

VISIT AZURITYSOLUTIONS.COM

References:

1. Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children. Pediatrics. 2017;140(3):e20171904. 2. Katerzia [package insert]. Wilmington, MA: Azurity Pharmaceuticals Inc; 2020. 3. Qbrelis [package insert]. Wilmington, MA: Azurity Pharmaceuticals Inc; 2020. 4. Drugs@FDA: FDA-Approved Drugs. Search term: lisinopril. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process. Accessed January 19, 2023. 5. Gutierrez-Colina AM, Smith AW, Mara CA, Modi AC. Adherence barriers in pediatric epilepsy: from toddlers to young adults. Epilepsy Behav. 2018;80:229-234. 6. Bhosle M, Benner JS, DeKoven M, Shelton J. Difficult to swallow: patient preferences for alternative valproate pharmaceutical formulations. Patient Prefer Adherence. 2009;3:161-171. 7. Chappell F. Medication adherence in children remains a challenge. Prescriber. 2015;26(12):31-34. 8. Zajicek A, Fossler MJ, Barrett JS, et al. A report from the Pediatric Formulations Task Force: perspectives on the state of child-friendly dosage forms. AAPS J. 2013;15(4):1072-1081. 9. Bachynsky J, Wiens C, Melnychuk K. The practice of splitting tablets: cost and therapeutic aspects. Pharmacoeconomics. 2002;20(5):339-346. 10. Gill D, Spain M, Edlund BJ. Crushing or splitting medications: unrecognized hazards. J Gerontol Nurs. 2012;38(1):8-12. 11. US Food and Drug Administration. Guidance for Industry. Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation. March 2013. 12. US Department of Health and Human Services. National Institutes of Health. Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics. https://www.nichd.nih.gov/sites/default/files/inline-files/2020PriorityListFeb20.pdf. Accessed February 13, 2023. 13. McGrady ME, Hommel KA. Medication adherence and health care utilization in pediatric chronic illness: a systematic review. Pediatrics. 2013;132(4):730-740. 14. Matsui D. Current issues in pediatric medication adherence. Pediatr Drugs. 2007;9(5):283-288. 15. Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1-8. 16. Allen LV Jr. Amlodipine 1 mg/mL oral liquid. US Pharm. 2014;39(2):55-56. 17. Lisinopril 1-mg/mL oral liquid. Int J Pharm Compound. 2006;10(4):302. 18. US Government Accountability Office. Compounded Drugs: Payment Practices Vary Across Public Programs and Private Insurers, and Medicare Part B Policy Should be Clarified. Report GAO-15-85. October 2014. https://www.gao.gov/products/gao-15-85. Accessed November 2, 2022. 19. US Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry. January 2018. 20. Watson CJ, Whitledge JD, Siani AM, Burns MM. Pharmaceutical compounding: a history, regulatory overview, and systematic review of compounding errors. J Med Toxicol. 2021;17(2):197-217. 21. Sellers S, Utian WH. Pharmacy compounding primer for physicians: prescriber beware. Drugs. 2012;72(16):2043-2050.